首页> 外文期刊>Bone marrow transplantation >Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
【24h】

Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.

机译:在半同种异体小鼠模型中诱导骨髓移植受体的口服耐受性可抑制移植物抗宿主病。

获取原文
获取原文并翻译 | 示例
           

摘要

Graft-versus-host disease (GVHD) is the major obstacle for successful allogeneic stem cell transplantation (SCT). Morbidity and mortality are high, and novel therapeutic strategies are required. Current therapy, which is based mainly on immunosuppression, is associated with a high degree of complications. Immune hyporesponsiveness induced by oral antigen administration has recently been shown to prevent the development of chronic GVHD (cGVHD) in a murine model. The aim of the present study was to evaluate whether it is possible to induce tolerance and to alleviate GVHD in a semiallogeneic transplantation model in mice. GVHD was generated by infusing 2 x 10(7) splenocytes from C57BL/6 donor mice into (C57BL/6 x Balb/c)F1 recipient mice, which received 7 Gy (60)Co total body irradiation (TBI) prior to transplantation. Oral tolerance was induced by feeding recipient F1 mice with five oral doses of proteins, 50 micro g/mouse, extracted from C57BL/6 splenocytes on alternate days following transplantation. In vitro mixed lymphocyte reaction (MLR) from tolerized and nontolerized mice was performed. Recipient mice were followed for chimerism, and for clinical and histological parameters of GVHD. Induction of tolerance was documented by a significant reduction in MLR response of tolerated vs nontolerated splenocytes. A significant alleviation of the clinical and pathological manifestation of GVHD was observed in the liver, small bowel, and skin. Tolerance induction did not jeopardize engraftment. These results may constitute a step towards reducing the frequency of GVHD via manipulation of the immune system.
机译:移植物抗宿主病(GVHD)是成功进行同种异体干细胞移植(SCT)的主要障碍。发病率和死亡率很高,因此需要新的治疗策略。当前主要基于免疫抑制的疗法与高度并发症相关。最近显示,口服抗原引起的免疫反应低下可预防鼠模型中慢性GVHD(cGVHD)的发展。本研究的目的是评估在小鼠的半同种异体移植模型中是否有可能诱导耐受和减轻GVHD。 GVHD是通过将来自C57BL / 6供体小鼠的2 x 10(7)脾细胞注入(C57BL / 6 x Balb / c)F1受体小鼠体内产生的,小鼠在移植前接受了7 Gy(60)Co全身照射(TBI)。通过在移植后隔天从C57BL / 6脾细胞中提取5种口服剂量的蛋白质(50微克/小鼠),为受体F1小鼠喂食来诱导口服耐受。进行了来自耐受和非耐受小鼠的体外混合淋巴细胞反应(MLR)。跟踪接受小鼠的嵌合体,以及GVHD的临床和组织学参数。通过耐受的脾细胞对非耐受的脾细胞的MLR应答的显着降低来证明耐受性的诱导。在肝脏,小肠和皮肤中观察到GVHD的临床和病理表现明显减轻。耐受诱导不会危害植入。这些结果可能构成通过操纵免疫系统降低GVHD频率的一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号